Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH - Kaatz - 2015 -
Anthos' Blood Thinner Abelacimab Outperforms Rivals in Safety by 67% in AF Patients
Non-major bleeding risk of direct oral anticoagulants versus vitamin K antagonists for stroke prevention with atrial fibrillation: a systematic review and network meta-analysis | European Journal of Clinical Pharmacology
A Phase IV Study of Thromboembolic and Bleeding Events Following Hip and Knee Arthroplasty Using Oral Factor Xa Inhibitor - ScienceDirect
Individual Benefits and Harms of Extended Anticoagulation in Patients with Venous Thromboembolism: The VTE-PREDICT Model - ISTH Congress Abstracts
PPT - John H. Alexander, MD, MHSc Duke Clinical Research Institute, Durham, NC, USA Lars Wallentin, MD, PhD Uppsala Clinical R PowerPoint Presentation - ID:154927
Abstract 12434: Long-Term Clinical Outcomes After Major versus Minor Bleeding in Patients With Atrial Fibrillation: The Fushimi AF Registry | Circulation
Identification of International Society on Thrombosis and Haemostasis major and clinically relevant non-major bleed events from electronic health records: a novel algorithm to enhance data utilisation from real-world sources | International Journal
Characterization of Major and Clinically Relevant Non-Major Bleeds in the APEX Trial
Cost–utility analysis of apixaban compared with usual care for primary thromboprophylaxis in ambulatory patients with cancer | CMAJ
Direct Oral Anticoagulants: A User's Guide | Consultant360
Management and outcomes of vaginal bleeding and heavy menstrual bleeding in women of reproductive age on direct oral anti-factor Xa inhibitor therapy: a case series - The Lancet Haematology
Were Major Bleeds Defined in the Same Way - Novel Oral Anticoagulants - Recent Advances in Oral Anticoagulation Therapy for Patients with Atrial Fibrillation
Long-Term Risk of Clinically Relevant Non-Major Bleeding During Extended Anticoagulation for Unprovoked Venous Thromboembolism: A Systematic Review and Meta-Analysis - ISTH Congress Abstracts
PACIFIC-AF: Low bleeding rates for asundexian in atrial fibrillation - Medical Conferences
Oral anticoagulation versus antiplatelet therapy for secondary stroke prevention in patients with embolic stroke of undetermined source: A systematic review and meta-analysis - Nikhil Nair Hariharan, Kashyap Patel, Omaike Sikder, Kanjana S
Clinically relevant non-major bleeding and intra-cranial haemorrhage in... | Download Scientific Diagram
Anthos Therapeutics' Novel Dual-Acting Factor XI/XIa Inhibitor, Abelacimab 150 mg, Demonstrated a 67%
Anticoagulation strategies and clinical outcomes after bleeding events during anticoagulation therapy for venous thromboembolism in the practice-based Japanese registry | Journal of Thrombosis and Thrombolysis
Practical Management of Anticoagulation in Patients With Atrial Fibrillation | Journal of the American College of Cardiology
Safety outcome of major bleeding or clinically relevant non-major bleeding. | Download Scientific Diagram
Nephrology Journal Club on X: "T1h: Outcomes were defined accordingly with International Society on Thrombosis and Haemostasis @isth #NephJC https://t.co/b0tQMjYKbE" / X
CRNM - "Clinically Relevant Non-Major Bleeding" by AcronymsAndSlang.com
WarfarinApixaban Primary outcome: major/clinically relevant bleeding (through 6 months) Secondary objective: Death, MI, stroke, stent thrombosis Randomize. - ppt download
